GlaxoSmithKline plc (LON:GSK) insider Simon Dingemans bought 7 shares of the company’s stock in a transaction that occurred on Tuesday, October 11th. The stock was bought at an average price of GBX 1,728 ($21.39) per share, with a total value of £120.96 ($149.70).
GlaxoSmithKline plc (LON:GSK) traded down 1.11% on Wednesday, reaching GBX 1700.00. 6,394,002 shares of the company traded hands. The company has a 50-day moving average price of GBX 1,647.81 and a 200-day moving average price of GBX 1,559.14. GlaxoSmithKline plc has a 12 month low of GBX 1,277.25 and a 12 month high of GBX 1,745.56. The company’s market capitalization is GBX 82.64 billion.
The business also recently disclosed a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be issued a dividend of GBX 19 ($0.24) per share. This represents a yield of 1.12%. The ex-dividend date is Thursday, August 11th.
Several analysts recently weighed in on the stock. Credit Suisse Group AG reiterated a “neutral” rating and issued a GBX 1,800 ($22.28) target price on shares of GlaxoSmithKline plc in a report on Thursday, July 14th. S&P Global Inc. set a GBX 1,650 ($20.42) target price on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a report on Wednesday, July 27th. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a report on Tuesday, June 21st. BNP Paribas restated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. Finally, Citigroup Inc. set a GBX 1,800 ($22.28) price target on shares of GlaxoSmithKline plc and gave the stock a “buy” rating in a research note on Thursday, September 29th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline plc currently has an average rating of “Hold” and an average price target of GBX 1,685.04 ($20.85).